Coronary Trials

  • EVOLVE SHORT DAPT

The EVOLVE Short DAPT Study is a prospective, multicenter, single-arm study designed to assess the safety of 3-month DAPT in subjects at high risk for bleeding undergoing PCI with a SYNERGY Stent System.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://www.clinicaltrials.gov/ct2/show/NCT02605447

 

  • XIENCE

XIENCE Short DAPT study is a prospective, single arm, multi-center, open label trial to evaluate the safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary intervention (PCI) with the approved XIENCE family of coronary drug-eluting stents

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT03218787?term=xience+short+dapt&rank=1

Peripheral Trials

  • CONFIDENCE

A prospective, multicenter, single-arm, open label clinical study to evaluate the safety and effectiveness of MicroVention, Inc. Roadsaver™ Carotid Stent System used in conjunction with the Nanoparasol® embolic protection system for the treatment of carotid artery stenosis in patients with elevated risk for adverse events following carotid endarterectomy.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://www.clinicaltrials.gov/ct2/show/NCT02657707

 

  • LUTONIX BTK

A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Comparing the Lutonix Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Below-the-Knee (BTK) arteries

 If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT01870401

 

  • CREST II

Carotid revascularization and medical management for asymptomatic carotid stenosis trial

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT02089217

 

  • LEOPARD

Multicenter, Observational, Post-Market, Real World Study to Assess Outcomes of Patients Treated with the AFX System compared to other EVAR devices for Endovascular Abdominal Aortic Aneurysm Repair

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT02407457

 

  • VOYAGER

An international, multicenter, randomized, double-blind, placebocontrolled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT02400905

 

  • DISRUPT PAD

Randomized study of the Shockwave Medical Peripheral Lithoplasty® System used in combination with DCB versus standard balloon angioplasty used in combination with DCB to treat moderate and severely calcified femoropopliteal arteries (Disrupt PAD III).

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT02923193?term=disrupt+pad&rank=3

 

  • ROX

A prospective, randomized, adaptive, double-blind, sham-controlled, multicenter study to evaluate the ROX Coupler in subjects with hypertension.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT02895386?term=rox&draw=1&rank=4

 

  • Toba BTK

This is a prospective, multi-center, single-arm, non-blinded study designed to investigate the safety and efficacy of the Tack Endovascular System.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT02942966?term=Toba+btk&rank=2

 

  • TRANSCEND DCB

The Randomized And Controlled Noninferiority Trial to Evaluate Safety and Clinical Efficacy of the SurVeil™ Drug-Coated Balloon iN the Treatment of Subjects With Stenotic Lesions of the Femoropopliteal Artery Compared to the Medtronic IN.PACT® Admiral® Drug-Coated Balloon.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://www.clinicaltrials.gov/ct2/show/NCT03241459?term=Transcend+DCB&rank=1

Structural Heart Trials

  • REPRISE III

REpositionable Percutaneous Replacement of Stenotic Aortic Valve through Implantation of Lotus™ Valve System – Randomized Clinical Evaluation: To evaluate the safety and effectiveness of the Lotus™ Valve System for transcatheter aortic valve replacement (TAVR) in symptomatic subjects with calcific, severe native aortic stenosis who are considered at extreme or high risk for surgical valve replacement.

 If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT02202434

 

  • PARTNER 3

To establish the safety and effectiveness of the Edwards SAPIEN 3 Transcatheter Heart Valve in patients with severe, symptomatic aortic stenosis who are at low operative risk for standard aortic valve replacement (AVR).  Prospective, randomized, controlled, multi-center trial. Patients having an operative mortality < 2% (low operative risk) for surgical aortic valve replacement will be randomized 1:1 to receive either transcatheter heart valve replacement (TAVR) with the Edwards SAPIEN 3 or aortic valve replacement with a commercially available surgical bioprosthetic valve. Patients will be seen for follow-up visits at discharge, 30 days, 6 months, and annually through 10 years.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://www.clinicaltrials.gov/ct2/show/NCT02675114

 

  • EARLY TAVR

To establish the safety and effectiveness of the Edwards SAPIEN 3 (Edwards Lifesciences, Irvine, California) Transcatheter Heart Valve (THV) compared with clinical surveillance (CS) in asymptomatic patients with severe, calcific aortic stenosis

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT03042104?term=early+tavr&draw=1&rank=1

 

  • LAMPOON

Intentional laceration of the anterior mitral leaflet to prevent left ventricular outflow tract obstruction during transcatheter mitral valve implantation.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://www.clinicaltrials.gov/ct2/show/NCT03015194?term=LAMPOON&rank=1

EP Trials

  • ADAPT RESPONSE

Medtronic, Inc. is sponsoring the AdaptResponse study; a prospective, randomized, controlled, interventional, single-blinded, multi-center, post-market, global Cardiac Resynchronization Therapy (CRT) in heart failure (HF) clinical study. The purpose of this clinical study is to test the hypothesis that market released CRT devices which contain the AdaptivCRT® (aCRT) algorithm have a superior outcome compared to standard CRT devices in CRT indicated patients with normal atrio-ventricular (AV) conduction and left bundle branch block (LBBB).

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT02205359

 

  • ATTAIN

The Attain Stability Quad Clinical Study is a prospective, non-randomized, multi-site, global, investigational Device Exemption (IDE) interventional clinical study. The purpose of this clinical study is to evaluate the safety and efficacy of the Attain Stability Quad MRI SureScan LV lead (Model 4798) in patients indicated for a de novo LV lead implant. This will be assessed through primary safety and primary efficacy endpoints.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT03099655?term=attain&draw=1&rank=3

 

  • ARTESIA

Prospective, randomized, parallel group, double-blind trial To determine if the use of apixaban in patients with SCAF will reduce the incidence of stroke and systemic embolism compared to aspirin.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT01938248?term=artesia&draw=1&rank=1

 

  • SMART CRT

SMART CRT is a prospective, double-blind, multicenter, international, randomized controlled trial. The primary objective is to show the benefit of SmartDelay™ in patients with a prolonged RV-LV interval.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT03075215?term=smart+crt&rank=2

Heart Failure Trials

  • CHAMP HF

Observational Registry of Treatment Patterns in the U.S. Heart Failure Patients with Reduced Ejection Fraction

If you would like additional information regarding this trial please contact researchopportunities@prairieresearch.com

 

  • CONNECT-HF

 This trial will be a large-scale, pragmatic, cluster-randomized clinical trial to evaluate the effect of 2 quality improvement (QI) initiatives compared with the usual care on heart failure (HF) outcomes and HF quality of care metrics in the year following discharge for participants hospitalized with acute HF and reduced ejection fraction (EF). All participants  in the trial will be consented for longitudinal follow-up as part of the CONNECT_HF registry on clinical outcomes, medication use, and participant-centered outcomes, including quality of life (QOL) assessments, at 6 weeks and 3, 6, 12 months after discharge.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT03035474?term=connect+hf&rank=1

 

  • BEAT-HF

The purpose of this clinical trial is to develop valid scientific evidence for safety and effectiveness of Baroreflex Activation Therapy™ with the Barostim neo system in subjects with heart failure, defined as New York Heart Association (NYHA) functional Class III and left ventricular ejection fraction (LVEF) ≤ 35% despite being treated with the appropriate heart failure guideline directed therapy, excluding subjects eligible for or with a Cardiac Resynchronization Therapy (CRT) device.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT02627196?term=beat+hf&draw=1&rank=3

 

  • PARADISE

A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to Ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction.

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT02924727?term=paradise-mi&rank=1

 

  • PERSPECTIVE

A Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Heart Failure and Preserved Ejection Fraction

If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com

https://clinicaltrials.gov/ct2/show/NCT02884206?term=PERSPECTIVE&draw=1&rank=8

More Coming soon…..